Emami Ltd
EMAMILTDEmami Ltd is cheap for a reason. The P/E sits at the 6th percentile of its own range, and the quarters are still getting worse.
The sharpest disagreement: annual EPS moved −3.9% against a −35.7% price move — the market has not yet caught up with the delivery.
The price is in a downtrend (58 weeks in) while the P/E sits at the 6th percentile of its own 10-year range. Underneath, the last four quarters read deteriorating — profit −11.7% year on year, and 108% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Emami Ltd trades at ₹398, in a downtrend and 58 weeks into that stage. That is −13.7% against its own 200-day average. It sits at 6% of a 52-week range of ₹385 to ₹605. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (1 week and counting).
Today the stock is in a downtrend — week 58 of stage 4, confirmed. At ₹398 it trades −13.7% versus its 200-day average and sits at 6% of its 52-week range (₹385–₹605).
Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved −15% while the NIFTY 500 moved +276% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (1 week and counting; last ahead the week of 2026-07-24) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Emami Ltd trades at 22.2× P/E, near the bottom of its own range — cheaper only 6% of the time. Its long-run median P/E is 42.5×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 22.2× is near the bottom of its own range — cheaper only 6% of the time, against a long-run median of 42.5× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved −3.9% against a −35.7% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the −6.6%/yr price move, ~+12.0%/yr came from earnings growth and ~−18.6 pp from the multiple (compressing); over 10y, of the −3.5%/yr price move, ~+9.4%/yr came from earnings growth and ~−12.9 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Deteriorating Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Emami Ltd reads as deteriorating on its fundamental arc. Deteriorating — revenue, profit and EPS growth are shrinking (revenue growth −0.8% latest against +6.5% at its 12-quarter best), ROCE slipping at 29.8%. The read is built from 12 quarters across 4 curves, on full evidence.
🚨 Why it matters: falling curves mean every cheap-looking ratio below needs a discount for direction.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | −0.8% | +3.5% | +5.6% | +4.8% |
| Profit | −3.5% | +7.3% | +11.2% | +7.9% |
| EPS | −3.9% | +7.0% | +11.7% | +8.3% |
| Share price | −35.7% | −4.0% | −6.6% | −3.5% |
4-Factor Sector Score
37.6/100 — rank 10 of 12 in FMCG - Personal Care · 90% evidence confidence
Emami Ltd scores 37.6 out of 100 against the 12 companies it is compared with in FMCG - Personal Care, ranking 10. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 7.6 + 15 + 9.5 + 5.5 = 37.6. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Emami Ltd reported ₹925 Cr of revenue in the Mar 26 quarter, −3.9% year on year. Over 10 years it has compounded at 4.8% a year. The last full year, FY26, came in at ₹3,780 Cr. The last four reported quarters add to ₹3,780 Cr.
FY26 revenue came in at ₹3,780 Cr (−0.8% on the year), capping 10 years at 4.8% compound. The latest quarter (Mar 26) printed ₹925 Cr, −3.9% year on year.
Pace check: the last four quarters averaged −1.1% growth against the decade's 4.8% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew −0.8% over the last 4 quarters against +2.8%/yr over the last 8 — rolling over; TTM profit −3.6% vs +3.3%/yr — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Emami Ltd's operating margin is 20.0% in the Mar 26 quarter, −3.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 25.0% to 31.0%. The current quarter is running below every full year in that window.
The latest quarter's operating margin is 20.0%, −3.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 25.0%–31.0%.
🚨 Why the margin moved: operating margin went −2.6 pp year on year while gross margin went +2.5 pp — the loss came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Emami Ltd earned ₹143 Cr of net profit in the Mar 26 quarter, −11.7% year on year. Full-year FY26 profit was ₹775 Cr. The 10-year compound rate is 7.9%. That is 15.5% of the quarter's revenue. The same quarter a year earlier earned ₹162 Cr.
Mar 26 profit was ₹143 Cr, −11.7% year on year. On the full year, FY26 printed ₹775 Cr (−3.5%), and the 10-year compound rate is 7.9%.
🚨 Why profit moved: revenue contributed −3.9% and the margin −3.0 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit −4.7% vs revenue −1.1%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 108% of Emami Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹801 Cr of operating cash against ₹775 Cr of profit. After ₹66.0 Cr of capital spending, ₹735 Cr was left as free cash.
FY26: operating cash of ₹801 Cr against reported profit of ₹775 Cr, leaving free cash of ₹735 Cr after ₹66.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 108% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 108%: the cash cycle held roughly steady between FY21 and FY26 — so conversion tracks profitability rather than the cycle.
Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Emami Ltd's cash conversion cycle runs 8 days in FY26, down from 10 days in FY21. Capital spending ran ₹178 Cr over the last 3 years. At FY26 sales of ₹3,780 Cr each day of that cycle holds about ₹10.4 Cr, so roughly ₹83.0 Cr sits inside the business at any moment.
FY26: debtors at 33 days, inventory at 128 days — roughly 4.2 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 8 days, tighter than FY21's 10.
The full loop: cash goes out to suppliers and production on day 0; stock waits 128 days to sell; customers pay about 33 days after that; and suppliers themselves are paid at 153 days — netting out to the 8-day cycle.
In money terms: at FY26 sales of ₹3,780 Cr, each day of the cycle holds about ₹10.4 Cr — so the 8-day loop keeps roughly ₹83.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹178 Cr over the last 3 fiscal years against ₹541 Cr of depreciation — spending at or below maintenance level. Capital work-in-progress stands at ₹1.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Emami Ltd earns a ROCE of 30% in FY26. That is up from a trough of 18% in FY20. Return on invested capital clears the cost of that capital by +20.5 percentage points, so growth here adds value rather than only size. The wiring behind it is 20.5% net margin on 0.99× asset turns.
FY26 ROCE is 30%, recovered from a FY20 trough of 18% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 20.5% net margin × 0.99× asset turns × 1.31× balance-sheet leverage ≈ 26.6% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 32.5% − 12.0% = a +20.5 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Emami Ltd carries total debt of ₹162 Cr against shareholder equity of ₹2,922 Cr as of Mar 26, a debt-to-equity of 0.06 — effectively unlevered. On the annual view that ratio went from 0.14 in FY22 to 0.06 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹162 Cr against shareholder equity of ₹2,922 Cr — a debt-to-equity of 0.06. On the annual view, debt-to-equity went from 0.14 (FY22) to 0.06 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Foreign institutions cut 6.1 points of Emami Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 7.9% of the company. Domestic institutions moved +5.4 points over the same window, to 27.0%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: −6.1 points over 8 quarters to 7.9%; Domestic institutions: +5.4 points over 8 quarters to 27.0%; Promoters: +0.0 points over 8 quarters to 54.8%.
Why the register moved: rotation — foreign institutions −6.1 points against domestic institutions +5.4 points over 8 quarters, with promoters holding steady — one class of institutions handing the register to the other, not a verdict change by the people closest to the numbers.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Emami Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Bajaj Consumer Care LtdBAJAJCON | 73.0/100Favorable setup100% evidence | LEADER | 32.3/35 Revenue 25.1% · PAT 77% · OPM change 9 pp 100% evidence | 16.5/25 ROCE 30% · OPM 24% 100% evidence | 10.2/20 P/E 30.7× · PEG 1.64 100% evidence | 14.0/20 RS sector 43% · RS bench 38.5% · 1Y 123.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 32.3 + 16.5 + 10.2 + 14 = 73 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Hindustan Unilever LtdHINDUNILVR | 68.9/100Favorable setup94% evidence | ASLEEP | 25.1/35 Revenue 5.8% · PAT 38.3% · OPM change 0 pp 100% evidence | 14.0/25 ROCE 28.4% · OPM 23% 100% evidence | 17.6/20 P/E 44.8× · PEG 0.72 100% evidence | 12.2/20 RS sector 6.2% · RS bench -9.9% · 1Y -9.1%0 of 10 weeks ahead 70% evidence |
| Exact sum: 25.1 + 14 + 17.6 + 12.2 = 68.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Gillette India LtdGILLETTE | 66.1/100Favorable setup94% evidence | ASLEEP | 25.0/35 Revenue 8% · PAT 18.4% · OPM change -1 pp 100% evidence | 18.2/25 ROCE 90.6% · OPM 29% 100% evidence | 14.6/20 P/E 37.2× · PEG 1.7 100% evidence | 8.3/20 RS sector -1.4% · RS bench -11.7% · 1Y -28.6%0 of 10 weeks ahead 70% evidence |
| Exact sum: 25 + 18.2 + 14.6 + 8.3 = 66.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Marico LtdMARICO | 62.1/100Mixed-positive evidence78% evidence | BREAKING OUT | 21.4/35 Revenue 25.7% · PAT 9.3% · OPM change -1 pp 83% evidence | 16.6/25 ROCE 47% · OPM 16% 76% evidence | 5.8/20 P/E 64.5× · PEG — 50% evidence | 18.3/20 RS sector 16% · RS bench 12% · 1Y 25.5%7 of 12 weeks ahead 100% evidence |
| Exact sum: 21.4 + 16.6 + 5.8 + 18.3 = 62.1 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 5Dabur India LtdDABUR | 50.0/100Mixed-positive evidence94% evidence | ASLEEP | 19.6/35 Revenue 7.4% · PAT 10.9% · OPM change 0 pp 100% evidence | 14.0/25 ROCE 20.3% · OPM 20% 100% evidence | 7.4/20 P/E 37.7× · PEG 5.04 100% evidence | 9.0/20 RS sector 0.3% · RS bench -13.8% · 1Y -17.6%0 of 10 weeks ahead 70% evidence |
| Exact sum: 19.6 + 14 + 7.4 + 9 = 50 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Procter & Gamble Hygiene and Health Care LtdPGHH | 48.3/100Mixed-negative evidence94% evidence | ASLEEP | 12.1/35 Revenue -1.6% · PAT -4.7% · OPM change -9 pp 100% evidence | 18.1/25 ROCE 157% · OPM 19% 100% evidence | 13.7/20 P/E 35.3× · PEG 1.77 100% evidence | 4.4/20 RS sector -15.8% · RS bench -26.2% · 1Y -33.9%0 of 10 weeks ahead 70% evidence |
| Exact sum: 12.1 + 18.1 + 13.7 + 4.4 = 48.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 7Colgate-Palmolive (India) LtdCOLPAL | 46.3/100Mixed-negative evidence94% evidence | ASLEEP | 11.7/35 Revenue 3.8% · PAT -3.3% · OPM change -2 pp 100% evidence | 20.8/25 ROCE 108% · OPM 30% 100% evidence | 5.1/20 P/E 41.2× · PEG 6.07 100% evidence | 8.7/20 RS sector -1.5% · RS bench -4.3% · 1Y -6.3%0 of 10 weeks ahead 70% evidence |
| Exact sum: 11.7 + 20.8 + 5.1 + 8.7 = 46.3 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 8Godrej Consumer Products LtdGODREJCP | 42.6/100Mixed-negative evidence90% evidence | ASLEEP | 15.4/35 Revenue 7.7% · PAT 0.5% · OPM change 0 pp 88% evidence | 13.0/25 ROCE 18.8% · OPM 22% 100% evidence | 3.5/20 P/E 55.3× · PEG 5.47 100% evidence | 10.7/20 RS sector 1% · RS bench -6.5% · 1Y -12.1%0 of 10 weeks ahead 70% evidence |
| Exact sum: 15.4 + 13 + 3.5 + 10.7 = 42.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Zydus Wellness LtdZYDUSWELL | 42.4/100Mixed-negative evidence96% evidence | LEADER | 11.0/35 Revenue 46.2% · PAT -43.2% · OPM change -3 pp 88% evidence | 6.1/25 ROCE 4.9% · OPM 18% 100% evidence | 6.1/20 P/E 80.3× · PEG 1.75 100% evidence | 19.2/20 RS sector 26.5% · RS bench 21.9% · 1Y 37.3%11 of 12 weeks ahead 100% evidence |
| Exact sum: 11 + 6.1 + 6.1 + 19.2 = 42.4 · Decision use: Price leads the evidence: RS versus the benchmark is 21.9%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 10Emami Ltdthis pageEMAMILTD | 37.6/100Mixed-negative evidence90% evidence | ASLEEP | 7.6/35 Revenue -0.8% · PAT -3.6% · OPM change -3 pp 88% evidence | 15.0/25 ROCE 29.6% · OPM 20% 100% evidence | 9.5/20 P/E 22.2× · PEG 2.99 100% evidence | 5.5/20 RS sector -14.1% · RS bench -19.1% · 1Y -30.8%0 of 10 weeks ahead 70% evidence |
| Exact sum: 7.6 + 15 + 9.5 + 5.5 = 37.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Jyothy Labs LtdJYOTHYLAB | 36.6/100Mixed-negative evidence90% evidence | ASLEEP | 8.3/35 Revenue 3.3% · PAT 0.3% · OPM change -4.5 pp 88% evidence | 14.7/25 ROCE 24.6% · OPM 12.5% 100% evidence | 9.5/20 P/E 20× · PEG 5.15 100% evidence | 4.1/20 RS sector -20.8% · RS bench -25.1% · 1Y -41.2%0 of 10 weeks ahead 70% evidence |
| Exact sum: 8.3 + 14.7 + 9.5 + 4.1 = 36.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Polo Queen Industrial and Fintech LtdPQIF | 34.2/100Thin evidence · provisional50% evidence | 15.0/35 Revenue -25.8% · PAT -16.1% · OPM change 0.3 pp 53% evidence | 7.7/25 ROCE 2.5% · OPM 7.6% 57% evidence | 8.5/20 P/E 223× · PEG — 15% evidence | 3.0/20 RS sector -54.8% · RS bench -58.4% · 1Y -66%0 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 15 + 7.7 + 8.5 + 3 = 34.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Emami Ltd's share price today?
Emami Ltd trades at ₹398, −35.7% over the past year. The company is valued at ₹17,375 Cr. The stock sits at 6% of its 52-week range of ₹385–₹605, −13.7% versus its 200-day average. On the tape, the price is in a downtrend, 58 weeks in. — as of 31 July 2026.
What were Emami Ltd's latest quarterly results?
Emami Ltd reported revenue of ₹925 Cr and net profit of ₹143 Cr for the Mar 26 quarter. Revenue fell 3.9% and profit fell 11.7% year on year. Earnings per share were ₹3.28. The operating margin was 20.0%, 3.0 pp lower than a year earlier. — as of 31 July 2026.
What is Emami Ltd's revenue?
Emami Ltd reported revenue of ₹925 Cr in the Mar 26 quarter, −3.9% year on year. For the full FY26 fiscal year, revenue was ₹3,780 Cr (−0.8%). Over the last 10 years revenue compounded at 4.8% a year. — as of 31 July 2026.
What is Emami Ltd's profit?
Emami Ltd earned ₹143 Cr of net profit in the Mar 26 quarter, −11.7% year on year. Full-year FY26 profit was ₹775 Cr. The operating margin ran 20.0% in the latest quarter. — as of 31 July 2026.
What is Emami Ltd's market cap?
Emami Ltd's market capitalisation is ₹17,375 Cr at a share price of ₹398. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Emami Ltd's P/E ratio?
Emami Ltd trades at a P/E of 22.2×, at the 6th percentile of its own 10-year range, against a long-run median of 42.5×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Emami Ltd pay a dividend?
Yes — Emami Ltd's dividend payout was 34% of profit in FY26, and it recorded a payout in each of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is Emami Ltd overvalued?
On its own history, Emami Ltd looks cheap against its own history: its P/E of 22.2× has been cheaper only 6% of the time in 10 years (long-run median 42.5×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
Is Emami Ltd growing?
Not right now — Emami Ltd's latest numbers are shrinking: latest-quarter revenue −3.9% year on year, profit −11.7%, and the margin −3.0 pp at 20.0%. The 10-year compound rates are 4.8% (revenue) and 7.9% (profit). The earnings engine currently reads: deteriorating — as of 31 July 2026.
How is Emami Ltd performing?
Emami Ltd is in a downtrend, 58 weeks in. Its latest quarter's revenue fell 3.9% and profit fell 11.7% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 31 July 2026.
What stage is Emami Ltd in?
Deteriorating — revenue, profit and EPS growth are shrinking (revenue growth −0.8% latest against +6.5% at its 12-quarter best), ROCE slipping at 29.8%. The read comes from the last 12 quarters of growth (revenue growth −0.8% latest, profit growth −3.6% latest, eps growth −3.9% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.
Is Emami Ltd in an uptrend?
No — the price is in a downtrend (week 58 of stage 4), trading −13.7% versus its 200-day average and at 6% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Emami Ltd beating the market?
Not lately — on a trailing-13-week view Emami Ltd is currently behind the NIFTY 500 (1 week and counting; last ahead the week of 2026-07-24), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved −15% against the NIFTY 500's +276% — behind the index over the full window. — as of 31 July 2026.
Will Emami Ltd's share price go up?
This page publishes no price forecast for Emami Ltd. What it measures instead: the share price is ₹398, the price is in a downtrend 58 weeks in. Its P/E of 22.2× sits at the 6th percentile of its own 10-year range. Direction is not something this site claims to know. — as of 31 July 2026.
Who owns Emami Ltd?
Promoters hold 54.8% of Emami Ltd, foreign institutions 7.9%, domestic institutions 27.0% and the public 10.3% (latest quarter). The biggest move on the register over the last two years: Foreign institutions cut 6.1 points over 8 quarters. — as of 31 July 2026.
Does Emami Ltd have too much debt?
No — Emami Ltd's debt-to-equity is 0.06, and operating profit covers the interest bill 87×. FY26 borrowings were ₹162 Cr against equity of ₹2,924 Cr. The returns on this page are earned, not borrowed — as of 31 July 2026.
What is Emami Ltd's capex?
Emami Ltd spent ₹178 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹66.0 Cr, with ₹1.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Emami Ltd's cash flow?
Emami Ltd generated ₹801 Cr of operating cash flow in FY26 and ₹735 Cr of free cash flow after ₹66.0 Cr of capital spending. Reported profit that year was ₹775 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Emami Ltd's profit real cash?
Yes — over the last 3 fiscal years, 108% of Emami Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹801 Cr against reported profit of ₹775 Cr. The cash then goes into a mix of the working-capital cycle and capacity. Cash-flow resolution is annual — as of 31 July 2026.
Where is Emami Ltd in its business cycle?
Emami Ltd's FY26 operating margin was 25.0%, against a 13-year band of 25.0%–31.0%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 20.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Emami Ltd story?
The sharpest disagreement: annual EPS moved −3.9% against a −35.7% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Emami Ltd a stock worth studying right now?
This is not investment advice. The machine read: Emami Ltd is cheap for a reason. The P/E sits at the 6th percentile of its own range, and the quarters are still getting worse. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.